LLDAS response rate observed in patients with SLE who received Descartes-08 in Phase 2 open-label trial reaching Month 3 follow-up (n=3) ...

Descartes Underwriting, the parametric risk transfer specialist, has adopted mea Platform’s artificial intelligence (AI) ...

Cartesian Therapeutics (RNAC) announced positive initial data from its ongoing Phase 2 open-label trial of Descartes-08 in patients with systemic ...

Descartes Systems Group (DSGX) is a strong buy with robust growth, AI-driven supply chain solutions, and attractive entry ...

Detailed price information for Descartes Sys Group (DSGX-Q) from The Globe and Mail including charting and trades.

BTIG raised the firm’s price target on Cartesian Therapeutics (RNAC) to $44 from $42 and keeps a Buy rating on the shares. The firm cites the ...

Ensure 100% driver compliance with realistic route plans to consistently meet fleet performance goals.

The SCMS market offers opportunities in AI, cloud, and blockchain integration, offering real-time visibility, predictive ...

Descartes Underwriting, a specialist underwriter of parametric risk transfer opportunities, has joined the International Cooperative and Mutual Insurance ...

Descartes Systems Group (TSX:DSG) has caught attention lately as investors study its recent performance in the software sector. Shares are reflecting shifting sentiment, and many are curious how the ...

Descartes Underwriting, a specialist in corporate parametric re/insurance solutions for climate and emerging risks, has ...